This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 13, 2012 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU) a specialty life science technology based company is pleased to announce it has entered into an Equity Purchase Agreement for up to
$10,000,000 of the Company's registered common stock by Southridge Partners II, LP ("Southridge"), an institutional investor based in
Ridgefield, Connecticut. This funding will enable the Company to further accelerate its commercial strategy of its Ygiene™ and Ogiene™ product lines.
Pursuant to the Agreement, the Company has the right, at its discretion, to sell to Southridge up to
$10 million of its common stock from time to time over a 36-month period. The Company will have the right, but is not obligated, to sell stock to Southridge depending on certain conditions as set forth in the Agreement. Both parties have also entered into a Registration Rights Agreement under which, the Company agreed to file a registration statement with the Securities and Exchange Commission with respect to the Shares. The ability to draw down funds pursuant to the Equity Purchase Agreement is conditioned on an effective registration statement.
Mark Lowenthal, BioNeutral Group, Inc. President and CEO, comments, "This is an important step for BioNeutral to have accomplished as a means to fund a portion of our working capital needs. Having won the backing of a forward-thinking institutional investor says a lot about their conviction regarding our vision, management team, and overall market demand. We believe that having a flexible and low cost funding instrument in place allows us to efficiently move our commercialization strategy forward."
About BioNeutral Group, Inc.
Headquartered in Morristown, New Jersey with lab facilities at the
New Jersey Institute of Technology in
Newark, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in
the United States and has previously been approved for sale in
Germany and it is also permitted to be sold in the UK,
Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit
Find us on Facebook:
Follow us on Twitter: